#'s will speak for themselves #’s will speak for themselves
$35M+ Revenue, $8+ Ebitda in Q4 2015.
$250M+ Revenue, $65+ Ebitda for 2016 with $.08 - $.10 EPS.
From a value perspective, we are far undervalued if you compare to others in the sector: NHC (even with its recent fallout), CRH, CXV, etc.
What has people worried here… Michael and Roger’s share selloff ? They still hold 4,000,000 shares each, not enough? You think they don’t care about the share price anymore?
Lowered guidance? At least they are being honest with us, and they understand it’s better to under promise and over deliver then vice versa. Even with the reduced projected figures we are still far undervalued.
New management? Who’s more qualified than a CEO and President who successfully grew a private healthcare company from scratch to $42M in Revenue and $10M+ in ebitda and expanded into 17 states.Sure, I listened to the conference call, maybe he’s not a great public speaker or has lots of experience with investor relations, but I could care less.
Too much focus on what’s going on in the very near term here IMO. 1 year from now when sentiment improves and PHM starts posting positive EPS we’ll look back in this period and think what a great buying opportunity that was. I currently hold a position well in the 6 figures and continue to add at these levels.
GLTA